Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio reports clinical, financial, and corporate updates tied to seralutinib, its investigational inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Recurring developments include Phase 3 study results, regulatory pathway updates, collaboration activity with Chiesi Group, quarterly financial results, and capital allocation updates.
Company news also covers Nasdaq Rule 5635(c)(4) employment inducement grants under the 2023 Employment Inducement Incentive Award Plan, investor conference participation, and business development or resource-allocation actions related to its pulmonary hypertension strategy.
Gossamer Bio (Nasdaq: GOSS) reported FDA, strategic, and capital structure updates centered on seralutinib for pulmonary arterial hypertension (PAH). Following a mid‑June 2026 Type B Pre‑NDA meeting and receipt of minutes, Gossamer plans a September 2026 NDA submission for PAH, supported by Phase 3 PROSERA plus Phase 2 TORREY confirmatory evidence. If filed, an FDA decision could occur in 3Q 2027.
Gossamer and Chiesi terminated their collaboration, returning worldwide development and commercial rights for seralutinib to Gossamer. Chiesi will make a $5 million one‑time payment and receive capped royalties and milestone payments, while Gossamer makes no upfront payment and regains full global operational control. At a July 14, 2026 special meeting, stockholders approved proposals tied to an exchange of $181.1 million (90.5%) of 5.00% Convertible Senior Notes due 2027 into $65.2 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030 plus equity and warrants, reducing total debt principal by about $115.9 million. Stockholders also authorized a reverse stock split to support Nasdaq bid‑price compliance, expected to be effected in or shortly after 3Q 2026, subject to Board decision. Gossamer preliminarily reported $57 million in cash, cash equivalents and marketable securities as of June 30, 2026 and announced a same‑day business update webcast.
Gossamer Bio (NASDAQ:GOSS) set key terms for its 7.50% Convertible Senior Secured First Lien Notes due 2030 and related purchase warrants.
The initial conversion rate is 5,347.5936 shares per $1,000 principal (about $0.19 per share). The initial warrant exercise price is $0.34 per share, based on a $0.17 reference price.
Gossamer Bio (NASDAQ:GOSS) reported final results of its exchange offer for its 5.00% Convertible Senior Notes due 2027. As of June 16, 2026, no additional notes were tendered beyond the $181.052 million previously exchanged, leaving $18.948 million outstanding.
The offer provided up to $72 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030, up to 317,647,058 common shares or prefunded warrants, and purchase warrants for eligible early tendering holders. A supplemental indenture removed substantially all restrictive covenants and certain events of default on the existing notes.
Gossamer Bio (NASDAQ:GOSS) reported early tender results for its exchange offer for 5.00% Convertible Senior Notes due 2027.
Holders tendered $181.052 million, or 90.526% of outstanding notes. The company lowered the minimum tender condition to 90.5% and expects early settlement on June 4, 2026, issuing new 7.50% secured notes and equity.
Gossamer Bio (NASDAQ:GOSS) extended the early tender date for its exchange offer and consent solicitation for 5.00% Convertible Senior Notes due 2027 to 5:00 p.m. ET on June 2, 2026.
Holders exchanging receive new 7.50% secured notes due 2030, equity securities, and, for early tenders, purchase warrants.
Gossamer Bio (NASDAQ:GOSS) launched an exchange offer and consent solicitation for its $200 million 5.00% Convertible Senior Notes due 2027, targeting elimination of over $120 million of debt with support from holders of approximately 75.2% of the notes.
Eligible institutional holders may exchange into new 7.50% first-lien convertible notes due 2030, common stock or prefunded warrants, and, for early tenders, additional purchase warrants. The offer runs through June 16, 2026, subject to a 98% minimum tender condition and other customary terms.
Gossamer Bio (Nasdaq:GOSS) reported Q1 2026 results and key updates on seralutinib for PAH. An in‑person FDA Pre‑NDA Type B meeting is scheduled for mid‑June, with a planned NDA submission in September 2026 and potential FDA decision in Q3 2027.
Exploratory PROSERA CT FRI data showed multiple nominally statistically significant multi‑compartment imaging effects correlated with clinical outcomes. Gossamer launched an exchange offer for its $200M 5.00% convertible notes, which upon full participation would cut convertible debt to $72M. Q1 cash was $99.2M, with runway into Q1 2027.
Gossamer Bio (Nasdaq:GOSS) will report its first quarter 2026 financial results on Monday, May 18, 2026. Management will host a live conference call and webcast at 8:00 a.m. ET to discuss results and provide a corporate update for investors.
Gossamer Bio (Nasdaq: GOSS) reported Q4 and full-year 2025 results, provided a corporate update, and outlined next steps after PROSERA Phase 3 topline data.
Key points: PROSERA narrowly missed its prespecified alpha at Week 24; prespecified higher‑risk and CTD‑PAH subgroups showed larger 6MWD gains. Enrollment in the PH‑ILD SERANATA study is paused. Year‑end cash and marketable securities were $136.9 million, funding operations into Q1 2027.
Gossamer Bio (Nasdaq: GOSS) reported topline Phase 3 PROSERA results for seralutinib in pulmonary arterial hypertension (PAH). The primary endpoint showed a placebo‑adjusted 6MWD improvement of +13.3 m at Week 24 (p=0.0320), missing the prespecified alpha of 0.025. Key secondary endpoints favored seralutinib, including a -120.4 ng/L NT‑proBNP reduction (p=0.0002). Prespecified intermediate/high‑risk patients (n=234) achieved a +20.0 m placebo‑adjusted 6MWD (p=0.0207). Safety was generally consistent with prior studies, though transaminase elevations ≥3x ULN occurred in 13% of seralutinib patients versus 1% placebo. Gossamer plans to meet the FDA and paused SERANATA enrollment to evaluate regional results.